Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 2557

1.

Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies.

Ralla B, Stephan C, Meller S, Dietrich D, Kristiansen G, Jung K.

Crit Rev Clin Lab Sci. 2014 May 30:1-32. [Epub ahead of print]

PMID:
24878357
[PubMed - as supplied by publisher]
2.

[Comparative analysis of gene expression in normal and cancer human prostate cell lines].

Rosenberg IeE, Herashchenko HV, Kashuba VI.

Ukr Biokhim Zh. 2014 Mar-Apr;86(2):119-28. Ukrainian.

PMID:
24868918
[PubMed - indexed for MEDLINE]
3.

Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review.

Sargos P, Ferretti L, Gross-Goupil M, Orre M, Cornelis F, Henriques de Figueiredo B, Houédé N, Merino C, Roubaud G, Dallaudiére B, Richaud P, Fléchon A.

Prostate Cancer Prostatic Dis. 2014 May 6. doi: 10.1038/pcan.2014.17. [Epub ahead of print]

PMID:
24796290
[PubMed - as supplied by publisher]
4.

Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.

Arsov C, Jankowiak F, Hiester A, Rabenalt R, Quentin M, Schimmöller L, Blondin D, Antoch G, Albers P.

Anticancer Res. 2014 May;34(5):2459-66.

PMID:
24778061
[PubMed - indexed for MEDLINE]
5.

When is prostate cancer really cancer?

Berman DM, Epstein JI.

Urol Clin North Am. 2014 May;41(2):339-46. doi: 10.1016/j.ucl.2014.01.006. Epub 2014 Feb 21. Review.

PMID:
24725494
[PubMed - indexed for MEDLINE]
6.

Expression of hepatocyte growth factor activator inhibitor-1 (HAI-1) gene in prostate cancer: clinical and biological significance.

Hu C, Jiang N, Wang G, Zheng J, Yang W, Yang J.

J BUON. 2014 Jan-Mar;19(1):215-20.

PMID:
24659667
[PubMed - indexed for MEDLINE]
7.

Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer.

Wang C, Wang L, Su B, Lu N, Song J, Yang X, Fu W, Tan W, Han B.

Prostate. 2014 May;74(7):689-701. doi: 10.1002/pros.22787. Epub 2014 Mar 12.

PMID:
24619958
[PubMed - indexed for MEDLINE]
8.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ.

J Clin Oncol. 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10.

PMID:
24616308
[PubMed - indexed for MEDLINE]
9.

An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.

Bristow RG, Berlin A, Dal Pra A.

Br J Radiol. 2014 Mar;87(1035):20130753. doi: 10.1259/bjr.20130753. Epub 2014 Feb 3. Review.

PMID:
24588670
[PubMed - indexed for MEDLINE]
10.

Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.

Lara PN Jr, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD.

J Natl Cancer Inst. 2014 Apr;106(4):dju013. doi: 10.1093/jnci/dju013. Epub 2014 Feb 24.

PMID:
24565955
[PubMed - indexed for MEDLINE]
11.

Distinguishing indolent from aggressive prostate cancer.

Culig Z.

Recent Results Cancer Res. 2014;202:141-7. doi: 10.1007/978-3-642-45195-9_17.

PMID:
24531788
[PubMed - indexed for MEDLINE]
12.

Prognostic value of a cell cycle progression score for men with prostate cancer.

Cuzick J.

Recent Results Cancer Res. 2014;202:133-40. doi: 10.1007/978-3-642-45195-9_16.

PMID:
24531787
[PubMed - indexed for MEDLINE]
13.

Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP).

Kitagawa Y, Ueno S, Izumi K, Mizokami A, Hinotsu S, Akaza H, Namiki M.

J Cancer Res Clin Oncol. 2014 Apr;140(4):673-9. doi: 10.1007/s00432-014-1612-8. Epub 2014 Feb 13.

PMID:
24522405
[PubMed - indexed for MEDLINE]
14.

Prognostic prostate tissue biomarkers of potential clinical use.

Van der Kwast TH.

Virchows Arch. 2014 Mar;464(3):293-300. doi: 10.1007/s00428-014-1540-7. Epub 2014 Feb 1. Review.

PMID:
24487790
[PubMed - indexed for MEDLINE]
15.

Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens.

Kimura K, Tsuzuki T, Kato M, Saito AM, Sassa N, Ishida R, Hirabayashi H, Yoshino Y, Hattori R, Gotoh M.

Prostate. 2014 May;74(6):680-7. doi: 10.1002/pros.22786. Epub 2014 Jan 31.

PMID:
24481730
[PubMed - indexed for MEDLINE]
16.

Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues.

Maiques O, Santacana M, Valls J, Pallares J, Mirantes C, Gatius S, García Dios DA, Amant F, Pedersen HC, Dolcet X, Matias-Guiu X.

Hum Pathol. 2014 Mar;45(3):522-32. doi: 10.1016/j.humpath.2013.10.018. Epub 2013 Nov 7.

PMID:
24457075
[PubMed - indexed for MEDLINE]
Free Article
17.

Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris MJ, Small EJ.

J Clin Oncol. 2014 Mar 1;32(7):671-7. doi: 10.1200/JCO.2013.52.3696. Epub 2014 Jan 21. Erratum in: J Clin Oncol. 2014 May 1;32(13):1387.

PMID:
24449231
[PubMed - indexed for MEDLINE]
18.

ERRα augments HIF-1 signalling by directly interacting with HIF-1α in normoxic and hypoxic prostate cancer cells.

Zou C, Yu S, Xu Z, Wu D, Ng CF, Yao X, Yew DT, Vanacker JM, Chan FL.

J Pathol. 2014 May;233(1):61-73. doi: 10.1002/path.4329. Epub 2014 Feb 5.

PMID:
24425001
[PubMed - indexed for MEDLINE]
19.

Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.

Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, Ameye F, De Meerleer G.

Prostate. 2014 Feb;74(3):297-305. doi: 10.1002/pros.22750.

PMID:
24395565
[PubMed - indexed for MEDLINE]
20.

High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.

Grupp K, Wilking J, Prien K, Hube-Magg C, Sirma H, Simon R, Steurer S, Budäus L, Haese A, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis MC.

Eur J Cancer. 2014 Mar;50(4):852-61. doi: 10.1016/j.ejca.2013.12.003. Epub 2013 Dec 28.

PMID:
24380696
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk